Report Detail

Medical Devices & Consumables (Post-pandemic Era)-Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022

  • RnM4476225
  • |
  • 04 August, 2022
  • |
  • Global
  • |
  • 102 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Non-Alcoholic Steatohepatitis (NASH) Drugs industry at home and abroad, estimate the overall market scale of the Non-Alcoholic Steatohepatitis (NASH) Drugs industry and the market share of major countries, Non-Alcoholic Steatohepatitis (NASH) Drugs industry, and study and judge the downstream market demand of Non-Alcoholic Steatohepatitis (NASH) Drugs through systematic research, Analyze the competition pattern of Non-Alcoholic Steatohepatitis (NASH) Drugs, so as to help solve the pain points of various stakeholders in Non-Alcoholic Steatohepatitis (NASH) Drugs industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Non-Alcoholic Steatohepatitis (NASH) Drugs Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Non-Alcoholic Steatohepatitis (NASH) Drugs Market?
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Major Type of Non-Alcoholic Steatohepatitis (NASH) Drugs Covered in XYZResearch report:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Application Segments Covered in XYZResearch Market
Hospital Pharmacy
Online Provider
Retail Pharmacy

For any other requirements, please feel free to contact us and we will provide you customized report.


Table of Contents

    Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Value
          • 2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type
          • 2.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Value (%)
        • 2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Production
          • 2.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Production by Type
          • 2.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Production (%)

        3. The Major Driver of Non-Alcoholic Steatohepatitis (NASH) Drugs Industry

        • 3.1 Historical & Forecast Global Non-Alcoholic Steatohepatitis (NASH) Drugs Demand
        • 3.2 Largest Application for Non-Alcoholic Steatohepatitis (NASH) Drugs (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Non-Alcoholic Steatohepatitis (NASH) Drugs Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Non-Alcoholic Steatohepatitis (NASH) Drugs Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price Trend

        • 12.1 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in US (2018-2022)
        • 12.2 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in China (2018-2022)
        • 12.4 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in India (2018-2022)
        • 12.6 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Non-Alcoholic Steatohepatitis (NASH) Drugs

        14. Non-Alcoholic Steatohepatitis (NASH) Drugs Competitive Landscape

        • 14.1 AstraZeneca
          • 14.1.1 AstraZeneca Company Profiles
          • 14.1.2 AstraZeneca Product Introduction
          • 14.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Conatus Pharmaceuticals
          • 14.2.1 Conatus Pharmaceuticals Company Profiles
          • 14.2.2 Conatus Pharmaceuticals Product Introduction
          • 14.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Enzo Biochem
          • 14.3.1 Enzo Biochem Company Profiles
          • 14.3.2 Enzo Biochem Product Introduction
          • 14.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Galmed Pharmaceuticals
          • 14.4.1 Galmed Pharmaceuticals Company Profiles
          • 14.4.2 Galmed Pharmaceuticals Product Introduction
          • 14.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Genfit
          • 14.5.1 Genfit Company Profiles
          • 14.5.2 Genfit Product Introduction
          • 14.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Gilead
          • 14.6.1 Gilead Company Profiles
          • 14.6.2 Gilead Product Introduction
          • 14.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Horizon Pharma
          • 14.7.1 Horizon Pharma Company Profiles
          • 14.7.2 Horizon Pharma Product Introduction
          • 14.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Immuron
          • 14.8.1 Immuron Company Profiles
          • 14.8.2 Immuron Product Introduction
          • 14.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Intercept Pharmaceuticals
          • 14.9.1 Intercept Pharmaceuticals Company Profiles
          • 14.9.2 Intercept Pharmaceuticals Product Introduction
          • 14.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives
        • 14.10 Novo Nordisk
          • 14.10.1 Novo Nordisk Company Profiles
          • 14.10.2 Novo Nordisk Product Introduction
          • 14.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
          • 14.10.4 Strategic initiatives

        15. Conclusion

          16. Methodology and Data Source

          Summary:
          Get latest Market Research Reports on Non-Alcoholic Steatohepatitis (NASH) Drugs. Industry analysis & Market Report on Non-Alcoholic Steatohepatitis (NASH) Drugs is a syndicated market report, published as (Post-pandemic Era)-Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022. It is complete Research Study and Industry Analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

          Last updated on

          REPORT YOU MIGHT BE INTERESTED

          Purchase this Report

          $2,850.00
          $5,700.00
          2,348.40
          4,696.80
          2,775.90
          5,551.80
          380,503.50
          761,007.00
          226,888.50
          453,777.00
          Credit card Logo

          Related Reports


          Reason to Buy

          Request for Sample of this report